Journal for ImmunoTherapy of Cancer (Nov 2020)
401 Phase 1/2 study of novel HER2-targeting, TLR7/8 immune-stimulating antibody conjugate (ISAC) BDC-1001 with or without immune checkpoint inhibitor in patients with advanced HER2-expressing solid tumors
- Marcin Kowanetz,
- Manish Sharma,
- Jeeyun Lee,
- Leisha Emens,
- Keun-Wook Lee,
- Yoon-Koo Kang,
- Paula Pohlmann,
- Glenn Hanna,
- Ecaterina Ileana Dumbrava,
- Daniel Catenacci,
- Dejan Juric,
- Bob Li,
- Kathleen Moore,
- Mark Pegram,
- Antoinette Tan,
- Shelley Ackerman,
- Heidi LeBlanc,
- David Dornan,
- Michael Alonso,
- Edith Perez
Affiliations
- Marcin Kowanetz
- Aff1 grid.418158.10000000405344718Genentech, Inc. San Francisco CA USA
- Manish Sharma
- 4 Department of Emergency Medicine, NewYork-Presbyterian Queens, Flushing, New York, USA
- Jeeyun Lee
- Aff211 grid.264381.a000000012181989XSamsung Medical CenterSungkyunkwan University School of Medicine Seoul South Korea
- Leisha Emens
- Aff501 grid.21107.350000000121719311Johns Hopkins University School of Medicine Baltimore MD USA
- Keun-Wook Lee
- Aff10 0000 0004 0470 5905grid.31501.36Seoul National University Bundang HospitalSeoul National University College of Medicine Seongnam South Korea
- Yoon-Koo Kang
- Aff6 0000 0004 0533 4667grid.267370.7Asan Medical CenterUniversity of Ulsan College of Medicine Seoul South Korea
- Paula Pohlmann
- 7Georgetown University, Washington, DC, USA
- Glenn Hanna
- 2Dana-Farber Cancer Institute, Boston, MA, USA
- Ecaterina Ileana Dumbrava
- 2The University of Texas MD Anderson Cancer Center, Houston, TX, USA
- Daniel Catenacci
- 4University of Chicago, Chicago, IL, USA
- Dejan Juric
- 7Massachusetts General Hospital, Boston, MA, USA
- Bob Li
- 11Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Kathleen Moore
- 12Stephenson Cancer Center, Oklahoma City, OK, USA
- Mark Pegram
- 13Stanford University, Stanford, CA, USA
- Antoinette Tan
- 17Levine Cancer Institute, Atrium Health, Charlotte, NC, USA
- Shelley Ackerman
- 19Bolt Biotherapeutics, Redwood City, CA, USA
- Heidi LeBlanc
- 19Bolt Biotherapeutics, Redwood City, CA, USA
- David Dornan
- 19Bolt Biotherapeutics, Redwood City, CA, USA
- Michael Alonso
- 19Bolt Biotherapeutics, Redwood City, CA, USA
- Edith Perez
- 19Bolt Biotherapeutics, Redwood City, CA, USA
- DOI
- https://doi.org/10.1136/jitc-2020-SITC2020.0401
- Journal volume & issue
-
Vol. 8,
no. Suppl 3
Abstract
No abstracts available.